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INTRODUCTION 
Graves’ orbitopathy has been known for close to 200 years. Since its 
first description Graves’ disease with its complex manifestations and 
unpredictable clinical course has fascinated and frustrated internists, surgeons, 
ophthalmologists and immunologists alike. It is enigmatic by what mechanism 
the thyroid gland and ocular tissues interact, and in what ways the clinician 
may modify possible inter relationships. 
The literature is replete with diverse nomenclature, diagnostic 
groupings, classifications and eponyms, making it difficult to appreciate the 
nature of this disorder as it presents in the patient. 
Rootman refers to the orbital changes and ocular abnormalities as 
Graves’ orbitopathy because it is an orbital rather than an ophthalmic process. 
Mc Kenzie has given the most pragmatic current definition of Graves’ disease:  
A multisystem disorder of unknown etiology characterized by one or 
more of three clinical entities  
1. hyperthyroidism associated with diffuse hyperplasia of the 
thyroid gland  
2. infiltrative ophthalmopathy  
3. infiltrative dermopathy(localized pre-tibial myxoedema). 
 7
While thyroid and eye disturbances frequently co-occur, the 
manifestations in these two organs run a distinctly separate clinical course. 
Patients with thyroid disease often end up in Ophthalmologist’s Clinic, 
because of the problem of exophthalmous & lid retraction which cosmetically 
and socially lead to many problems in day to day life. So the role of 
ophthalmologists in thee patients is to effect a therapy that will restrict the 
progression of Thyroid Related Orbitopathy & to reduce the lid retraction 
either by medical or surgical modalities.  
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HISTORY 
As early as the 12th century, the Persian writings of Sayyid Ismail Al –
Jurjani described that exophthalmos is related to goiter. Parry in 1786 described 
Parry’s disease compromising-goitre, tachycardia and protrusion of eyes. 
Flajani(1802) and  Calebhillier followed by Graves’(1835) after whom the 
eponym of Graves’ disease followed, described an enlarged thyroid associated 
with palpitation and protrusion of eyes. 
Basedow (1799-1854) described exophthalmos as due to hypertrophy of 
orbital tissue caused by disordered circulation and discussed the three cardinal 
symptoms of exophthalmos, goitre and tachycardia. Hence the condition is 
frequently termed Basedow’s disease in German literature. Rehn (1884) and 
Moebius (1887) were the first to point to hyperthyroidism as the essential cause 
of exophthalmos. 
Malignant exophthalmos (Rosenbaum 1937; Ruedeman 1937) is a 
condition where the exophthalmos tends to be pronounced and intractable even 
in the absence of an associated thyrotoxicosis. 
This multiplicity of nomenclature was due to the ignorance of the 
aetiology of the condition. The autoimmune aetiology, which is proven, now 
has simplified the nomenclature as Graves’ disease. There are still many facets 
of this fascinating subject yet to be solved. 
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PIONEERS IN THE FIELD OF TRO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carl Adolph Basedow (1799-1854) 
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ANATOMY OF THE ORBIT 
The human orbital cavities are placed on either side of the sagittal plane 
of the skull between cranial and facial parts encroaching about equally on both. 
The orbit is essentially a socket containing the eyeball and the muscles, nerves, 
and vessels supplying it. Rest of the space in the orbit is occupied by fat, 
connective tissue and lacrimal gland. It also transmits certain vessels and 
nerves to supply areas around the orbital aperture. 
The orbit is composed of seven bones: frontal, sphenoid, zygomatic, 
maxillary, palatine, lacrimal and ethmoid. In shape, it is roughly a quadrilateral 
pyramid with an apex, base and four walls, which is directed forwards, 
laterally, and slightly downwards. 
The apex corresponds to the optic foramen, the base corresponds to the 
orbital margin, which opens on the face and the four walls, which form the 
roof, floor, lateral wall and the medial wall. The floor and the roof are roughly 
triangular, the lateral and medial walls quadrilateral and the floor does not 
reach up to the apex. The medial walls of the two orbits are parallel to each 
other. The orbital opening on the face does not correspond to the coronal plane 
and is inclined to it at an angle of 150 so that the medial wall reaches a more 
anterior position than the lateral wall. The medial wall is the thinnest, the floor 
the shortest and the lateral wall the strongest.   
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RIGHT ORBIT - VIEWED ALONG ITS AXIS 
(Courtesy Wolff's Anatomy of the Eye & Orbit) 
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EMBRYOLOGY AND DEVELOPMENT OF THE ORBIT 
The orbit develops from the mesoderm surrounding the optic vesicle and 
the optic stalk. The orbital mesoderm is derived from several sources. Above 
the mesodermal capsule of the forebrain, forms the roof of the orbit. Below and 
laterally, the maxillary process forms the floor and lateral walls of the orbit. 
Medially, the frontonasal process forms the medial wall of the orbit. The pre 
and orbitosphenoid, contributes to the roof, medial and lateral walls posteriorly. 
Of the seven orbital bones, the first to be laid down is the ethmoid at 6-8 
weeks of gestation. The trochlea begins to consolidate at about 9 week of 
gestation. Except for the lesser wing of the sphenoid, which is initially 
cartilaginous, all other bones of the orbit are membranous and begin to ossify 
during the third month. Fusion takes place between the sixth and seventh 
month. At birth orbit is 55% of adult size. It reaches 79% at 3 years and 94% at 
7 years of age. Generally, orbits do not grow much after 7 years. The growth of 
cranium, face and paranasal sinuses influence the shape and size of the orbit. 
The angle subtended by the orbital axes is nearly 1800 at first and diminishes to 
approximately 1050 at 3 months of gestation and at birth; the angle is 710. By 3 
years of age the orbital axes attains its adult condition of 680.  
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Hypothalamic TRH stimulates (+) pituitary, which releases thyroid-
stimulating hormone, which stimulates (+) the thyroid. Levels of T4 and T3 in 
blood provide information about FEED BACK REGULATION OF Thyroid 
function gland by the pituitary. 
 15
DISEASE STATES OF THE THYROID GLAND 
          The Thyroid gland is commonly affected by the following conditions: 
A:Thyroiditis 
B: Hyperthyroidism 
C: Hypothyroidism 
Hyperthyroidism – Also known as thyrotoxicosis, is a state in which 
there is an excess of circulating thyroid horomones, namely T3 or T4. It may be 
primary or secondary. Primary thyrotoxicosis is also known as Graves’ disease. 
The gland is diffusely enlarged and there are signs of a hypermetabolic state. 
The eyes may or may not be involved. Secondary thyrotoxicosis occurs when a 
patient with a previously abnormal gland (eg.Nodular goiter) assumes a hyper 
functional state. 
Hypothyroidism - implies the clinical manifestations due to lack of 
thyroid hormone. It may be idiopathic atrophic, Post – ablative (post surgical / 
external radio therapy), auto – immune, drug induced, congenital, secondary to 
pituitary or hypothalamic disease. 
Cretinism occurs in children and infants due to dysgenesis of thyroid 
gland or metabolic errors or chronic iodine deficiency in endemic regions.  
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CLINICAL FEATURES OF HYPERTHYROIDISM 
 Symptoms Signs 
General Anxiety,tremulousness,gener
alized weakness, heat 
intolerance, skin thinning and 
tanning, brittle hair, pruritis. 
Restlessness, objective weight 
loss, excessive sweating, hair 
thinning. 
CVS Palpitations, irregular beats 
and shortness of breath. 
Tachycardia, increased pulse 
pressure, ectopic beats, atrial 
fibrillation, sick sinus 
syndrome, cardiac failure. 
CNS Hyperactivity, muscle 
weakness, apathy in older 
age. 
Fine tremors, hyper-reflexia, 
proximal muscle weakness, 
and periodic paralysis. 
GIT Diarrhoea(non-infective) Rapid bowel transit time, 
steatorrhoea. 
Reproductive 
system 
Oligomenorrhoea or 
amenorrhoea, impotence. 
Gynecomastia, infertility. 
Thyroid 
gland 
Enlargement of gland, neck 
pressure symptoms 
Diffuse or nodular goiter, 
bruit, thrill. 
Eye Stare, gritty sensation, 
increased lacrimal secretion, 
diplopia, decreased colour 
and contrast vision, dry eyes, 
increased sensitivity to light, 
angry looking eyes, puffy 
lids. 
Lid retraction, lid lag, 
chemosis, 
proptosis(exophthalmos) 
infiltrative ophthalmopathy, 
ocular muscle paresis, 
exposure keratopathy. 
Skin Thyroid acropathy, clubbing 
of fingers 
Infiltrative dermopathy 
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CLINICAL FEATURES OF HYPOTHYROIDISIM 
 Symptoms Signs 
General Blunting of features, 
generalized slowing. 
Periorbital puffiness, 
psychomotor retardation. 
Skin Dryness, itching  Dry, rough and flaky skin, 
non pitting oedema, 
carotenaemia. 
Hair Hair loss and thinning  Coarse and brittle hair, 
selective areas of alopecia. 
CVS Shortness of breath, angina 
pectoris, congestive cardiac 
failure. 
Bradycardia, ischemic heart 
disease, pericardial effusion.
CNS Muscle aches and pains, 
slowing of motor function, 
deafness, somnolence, loss 
of memory, decreased 
concentration 
Delayed relaxation of 
tendon reflexes, myotonia 
and myxoedema, carpal 
tunnel syndrome, nerve 
conduction deafness, 
slowing of cerebration. 
GIT Constipation, weight gain Ileus, ascites. 
Reproductive 
System 
Menstrual irregularities 
(usually menorrhagia), 
infertility galatorrhoea. 
High FSH/ LH 
Haematological 
System 
Pallor, non-responsive 
anaemia, Bleeding 
tendencies. 
Dimorphic anaemia, 
Megaloblastic anaemia, 
coagulation defects. 
Miscellaneous Cold intolerance, thick and 
coarse speech, fatigue, 
muscle-cramps, arthritis. 
Hypothermia 
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Euthyroid ophthalmopathy 
Accounts for less than 10% of patients with presumed thyroid disease. It 
provides a difficult diagnostic challenge. By definition, in euthyroid disease, 
base line thyroid function test are normal. So in these cases thyroid stimulating 
hormone levels should be measured for confirmation.   
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PATHOLOGY AND PATHOPHYSIOLOGY OF THYROID 
RELATED ORBITOPATHY 
       Graves’ orbitopathy occurs in a generally pre-selected population, 
affecting females (usually middle aged), four to five times more frequently than 
males. The pathology of orbital involvement reflects the immuno-pathogenic 
mechanism. The major target affected is the extra-ocular muscles. 
PATHOPHYSIOLOGY 
The extra-ocular muscles are infiltrated by round cells i.e. lymphocytes, 
plasma cells and occasional mast cells. There is deposition of hydrophilic 
mucopolysacchrides, and the formation of collagen causes degenerative 
changes in the extra ocular muscles thus reflecting target effects of the disease 
on the orbital myocyte and the endomysial fibroblast. The plasma cells mediate 
the release of mucopolysaccharides and the formation of collagen by 
fibroblasts. There is usually a moderate inflammatory infiltration with plasma 
cells, lymphocytes and mast cells surrounding the blood vessels and muscle 
fibres. The muscle fibres appear distended and there is separation of the fibres 
by a loose, mucopolysaccharide rich stroma. With increasing severity and 
duration of inflammation, stromal collagen deposition occurs and muscle 
degeneration may be noted.  
Ultimately the disease passes into a more quiescent stage, when the 
degenerated muscle tissue may be replaced by fat. 
Orbital fibroblasts are susceptible to the action of pro-inflammatory 
cytokines. 
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IMMUNOLOGY 
 The immune system must be regarded as a homeostatic mechanism 
capable of responding to stimuli from the external environment and from the 
organism’s internal milieu. In order to respond, the system must have 
anatomical components receiving, processing, integrating, and reacting to 
immunological challenges. The immune network includes the afferent and 
efferent divisions. 
The Hypothesis put forth for the pathogenesis in the past 
a. Warthin’s concept of a thymico- lymphatic body, which is a 
consequence rather than a cause. 
b. Hyper function of the anterior pituitary, with release of excess 
thyroid stimulating hormone (thyrotropin) is disproved. Since in 
primary myxoedema also thyroid stimulating hormone increases, 
but there is no exophthalmos. 
c. Exophthalmos producing substances (EPS), distinct from 
thyrotropin. 
The Site of Immuno-Pathology 
Fibroblasts of the connective tissue stroma and basement membrane of 
the thyroid have been proven by immuno-fluorescent studies. As the target 
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cells in thyroid associated orbitopathy, sensitive to cytokines from 
lymphocytes.  
(i) Clinical Evidence 
 Patients with any or all manifestations of Graves’ disease have an 
increased incidence of other diseases known to have an immunologic basis. 
Thymic hyperplasia, lymphadenopathy and splenomegaly are findings often 
indicative of systemic immunological imbalance, may also be present. 
The effectiveness of the following treatment modalities : 
1. Systemic corticosteroids 
2. Immuno suppressive agents e.g: cyclosporine and 
cyclophosphamide  
3. Orbital irradiation  
Supports an immunological basis for the manifestations of the Graves’ 
disease. 
(ii) Humoral Evidence – Long Acting thyroid Stimulator (LATS) 
 This substance was indeed shown to be an IgG immunoglobulin, but 
only 50-60% of Graves’ thyrotoxic patients had detectable levels of LATS and, 
even when present, the LATS titre failed to correlate with either the thyroid or 
ophthalmic disease activity. 
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 Thyroid – stimulating immunoglobulins (TSI) have now replaced LATS 
as the suspect humoral factor. These IgG immunoglobulins, undetected by the 
LATS assay, have been found in the sera of over 90% of Graves’ thyrotoxic 
patients. Immune complexes are combinations of antibody and antigen. 
Immune complex binding to extra ocular muscle significantly exceeds binding 
affinity for other tissues. 
(iii) Cellular Evidence  
 The diffuse lymphocytic infiltration of orbital tissues that characterize 
Graves ophthalmopathy, and the high incidence of concurrent thymic 
abnormalities have logically led to investigation of the cellular immune system. 
Lymphocytes from patients with Grave’s disease had statistically significant 
migration inhibition factor (MIF) titres compared to lymphocytes from normal 
controls. 
In Caucasian patients with this “disorder”, an increased frequency of 
HLA-B8 has been reported. When a population of Japanese patients were 
investigated an increased incidence of HLA – BW 35 antigen was found. HLA 
– Cw3 and HLA – DR3 have also been reported to be associated with Grave’s 
disease. 
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Pro-Inflammatory Cytokines: 
 The following two cytokines production are increased in orbital 
fibroblasts 
1. PG HS2: An inflammatory cyclo oxygenase, which in turn 
increases production of PGE2. 
2. PGE2: The production of both is up regulated in the orbital 
fibroblasts and can be blocked by gluco-corticoids. 
The extra ocular muscles and peri-orbital connective tissue accumulate 
non-sulfated glycosaminoglycans – hyaluronan, accompanied by intense 
autoimmune inflammation. There is a doubling of the hyaluronic acid content 
in the orbital tissue which results in a five fold increase in the tissue osmotic 
load. The osmotic damage causes muscle oedema and proptosis. Subsequent 
fibrosis of muscle fibres and eventual tissue atrophy ensues. Active 
inflammation in the acute and sub- acute stages progresses to the quiescent 
stage and results in fibrosis. 
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THYROID EYE DISEASE 
The onset, course, severity and relationship to the systemic disease is 
variable. Grave’s orbitopathy usually occurs in association with 
hyperthyroidism but some patients with typical features of Grave’s orbitopathy 
may be hypothyroid or even euthyroid. 
CLINICAL FEATURES 
There are two stages in the development of the disease: 
1. Stage of Active Inflammation 
Where the eyes are red and painful. It usually remits within three years 
but 10% of the patients develop serious long-term ocular problems. 
2. Quiescent Stage 
Where the eyes are white but painless motility defects are present. The 
five main clinical manifestations of dysthyroid ophthalmopathy are  
1. Eyelid retraction 
2. Soft tissue involvement 
3. Proptosis 
4. Optic neuropathy 
5. Restrictive myopathy 
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EYELID RETRACTION 
 The normal position of the upper lid is 1-2mm below the upper limbus. 
Lid retraction leads to a characteristic starring appearance. 
Postulated mechanisms 
a. Contraction of the levator associated with fibrosis and local 
adhesions between levator and overlying orbital tissues. In the 
lower lid, fibrosis of the inferior rectus muscle may induce 
retraction via its capsulopalpebral head. 
b. Secondary overaction of levator – superior rectus complex in 
response to the hypohoria produced by fibrosis and tethering of 
the inferior rectus muscle (manifested by increased lid lag on 
shifting from down gaze to up gaze). Retraction of lower lid 
resulting from overaction of inferior rectus may also occur 
secondary to fibrosis of superior rectus muscle. 
c. Chemically induced overaction of Muller’s muscle as a result of 
sympathetic overstimulation secondary to high levels of thyroid 
hormone. 
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In general, lid retraction is thought to be due to a sympathomimetic 
response in the early stages, whereas in the later stages it may be associated 
with fibrosis of lid tissues. 
Signs and Symptoms of Soft Tissue Involvement 
Symptoms – Excessive lacrimation, gritty sensation, discomfort and 
photophobia.  
Signs  
a. Conjunctival Injection 
b. Chemosis 
c. Edema and Fullness of the Lids 
These often coexist, though sometimes oedema may be present without 
fullness. Lid fullness reflects oedema and infiltration behind the orbital septum 
whereas lid oedema alone is the result of fluid anterior to the orbital septum, 
just under the skin and orbicularis muscle. Periobital puffiness, usually worse 
in the mornings, is often the result of prolapse of retro-orbital fat into the lids. 
d. Superior Limbic Keratoconjunctivitis is a sensitive sign of soft 
tissue involvement  
 27
Proptosis  is a characteristic finding, seen in about 60% of the 
patients. The onset is usually insidious, and progression is gradual. 
Proptosis is typically axial and it occurs due to several causes.  
a. Enlargement of extra ocular muscle. Small changes in orbital 
volume may cause a significant increase in protosis. 
b. Increased orbital fat volume with or without muscle involvement.  
c. Venous stasis due to increased orbital pressure. Enlargement of 
superior rectus muscle alone may compress the Superior 
Ophthalmic Vein, resulting in reduced venous outflow from the 
orbit, thereby increasing the apparent orbital fat volume. 
Complications 
Exposure Keratitis 
This results from: 
- Inadequate lid closure due to proptosis and lid dysfunction. 
- Loss of the protective Bell’s phenomenon in patients with 
restrictive myopathy. 
Visual Loss 
 This is an important but rare complication of thyroid eye disease. It can 
be caused by: 
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- Dysthyroid optic neuropathy 
- Exposure keratopathy, with subsequent corneal ulceration and 
opacification or perforation with panophthalmitis and loss of the 
eye. 
Dysthyroid Optic Neuropathy 
 The incidence of optic neuropathy in thyroid disease is approximately 
5% and affected individuals usually do not have marked proptosis or optic 
nerve changes on ophthalmoscopy. The following are the signs and symptoms 
of this condition. 
Symptoms 
a. Ophthalmoscopic evidence of disc oedema or pallor  
b. Visual field defects 
c. Afferent papillary defect 
The neuropathy is probably caused by mechanical compression of the 
optic nerve. Examination of the ophthalmopathy patient with suspected optic 
neuropathy should include visual acuity, colour vision, pupillary examination 
for afferent pupillary defect, funduscopy, and visual field examination by 
perimetry. The most common visual field defects, paracentral scotomas, and 
generalized constriction of the visual field. 
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Restrictive Thyroid Myopathy – Between 30 –50% of hyperthyroid 
patients develop ophthalmoplegia. Ocular motility is restricted by oedema in 
the infiltrative phase and by fibrosis in the fibrotic phase. Typically, there is 
first a limitation of elevation followed later by a limitation of abduction, 
usually associated with diplopia in the corresponding fields of gaze. Most 
thyroid ophthalmopathy patients, including those with no ocular motility 
symptoms, show some degree of extra ocular muscle involvement by ultra-
sonography. 
CLASSIFICATION 
Eponymic Eye Signs in Graves’ Disease 
Lid Signs 
Upper Lid 
1. Boston’s sign  –  Uneven jerky motion of upper lid on inferior 
movement. 
2. Dalrymple’s sign  –  Upper lid retraction. 
3. Gifford’s sign  –  Difficult eversion of upper lid. 
4. Jellinek’s sign  –  Abnormal pigmentation of upper lid. 
5. Kocher’s sign  –  Spasmodic retraction of upper lid during 
fixation with staring look and frightening appearance of eyes.   
6. Von Graefe’s sign  –  Upper lid lag on downgaze. 
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Lower Lid 
1. Enroth’s sign  –  Oedema of lower lid. 
2. Griffith’s sign  –  Lower lid lag on upgaze. 
Both Upper and Lower lids 
1. Rosenbach’s sign  –  Tremor of gently closed lids. 
2. Vigouroux’s sign  –  Puffiness of lids. 
3. Riesman’s sign  –  Bruit over eyelids. 
On Upgaze 
1. Joffroy’s sign  –  Absent creases in forehead on superior gaze 
2. Mean’s sign  –  Increased superior scleral show on upgaze (Globe 
lag) 
3. Sainton’s sign  –  Frontalis contraction after cessation of levator 
activity 
On Downgaze 
1. Boston’s sign  –  as above 
2. Von Graefe’s sign  –  as above 
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Motility and Extra Ocular Muscles 
1. Ballet’s sign  –  Paralysis of one or more extra ocular muscles 
2. Moebius sign  –  difficult convergence  
3. Suker’s sign  –  Inability to maintain fixation on extreme lateral 
gaze 
4. Wilder’s sign  –  Jerking of eyes on movement from abduction to 
adduction 
Pupillary Signs 
1. Cowen’s sign  –  Extensive hippos of consensual pupillary light 
reflex 
2. Knies’ sign  –  Uneven pupillary dilatation in dim light 
3. Loewi’s sign  –  Dilatation of pupil with 1:1000 epinephrine 
On Blinking  
1. Pochin’s sign  –  Reduced amplitude of blinking 
2. Stellwag’s sign  –  Incomplete and infrequent blinkingOthers 
1. Goldzieher’s sign  –  Deep injection of conjunctiva, especially 
temporally  
2. Payne  –  Trousseau’s sign  –  Dislocation of the globe 
3. Riesman’s sign  –  as above 
4. Snellen  –  Donder’s sign  –  Bruit over eye 
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 The original classification for thyroid eye disease was given by Werner 
as Chair of the American Thyroid Association adhoc sub committee on eye 
disease-NO SPECS. Subsequently modified by American Thyroid Association 
(ATA) in 1997. 
Classification of Eye Changes of Grave’s Disease – Werner’s NOSPECS 
Class Grade Suggestion for Grading 
0 No physical signs or symptoms  
I Only signs – limited to upper lid retraction, lid lag 
II Soft Tissue involvement with symptoms and signs 
 0 - Absent 
 A - Minimal  
 B - Moderate  
 C - Marked 
III Proptosis 
 0 - Absent 
 A - 3-4 mm increase over upper normal 
 B - 5-7 mm increase over upper normal 
 C - 8 mm or more increase 
IV EOM Involvement  
 0 - Absent 
 A - Limitation of motion at extremes of gaze 
 B - Evident restriction of motion 
 C - Fixation of globe or globes 
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V Corneal Involvement  
 0 - Absent 
 A - Stippling of cornea 
 B - Ulceration 
 C - Clouding, necrosis, perforation 
VI Sight Loss Caused by Optic Nerve Involvement 
 0 - Absent 
 A - Disc pallor or chocking or visual field defect; 
vision 20/20 – 20/60 (6/6 – 6/18) 
 B - Vision 20/80 – 20/200 (6/24 – 6/60) 
 C - Vision <20/200 (<6/60) (blindness – failure to 
perceive light)  
 
The first letter of each class in the grading system spells the mnemonic   
NO SPECS. As shown in this table, each class in divided into four grades: 
absent (0), mild (a), moderate (b), and marked (c). 
Van Dyk proposed an expansion of Werner’s class II soft tissue 
changes with the mnemonic R E L I E F. 
R – Resistance to retro displacement of the eye. 
E – Edema of the conjunctiva  
L – Lacrimal gland enlargement  
I – Injection of conjunctiva 
E – Edema of lids 
F – Fullness of lids 
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The classification systems are intended to reflect the degree of severity 
of thyroid eye disease but do not indicate the course of disease progression. 
There are two major clinical groups: 
1. Non-Infiltrative Orbitopathy 
90% of cases fall under this category. This is the mild variety and is 
classified as class 0 or 1 in Werner’s NOSPECS classification. 
2. Infiltrative Disease 
Classes 2 through 6 have infiltrative disease and accounts for 10% of all 
cases of Grave’s hyperthyroidism. These patients have a more fulminant course 
with significant infiltration, inflammation and scarring. 
Thus Werner’s classification allows us to record the clinical status of a 
patient but does not reflect a continuum of disease or progression in an 
individual patient. 
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Course of the disease 
Thyroid opthalmopathy is typically a self-limited process that becomes 
quiescent within 3 to 5 years of its onset. Spontaneous remissions and 
exacerbations have been reported in thyroid opthalmopathy in the pre-treatment 
era. 
¾ Eyelid retraction may improve in upto 50% of the patients. 
¾ Proptosis usually remains stable once it reaches its maximum. 
¾ Ocular motility can also vary with time, and unless vision is 
threatened, patients should be followed up for periods of upto 6 
months to ensure stability before therapeutic intervention. 
¾ Visual loss – As many as 10% of patients with thyroid eye 
disease develop severe, vision threatening ophthalmopathy. 
Patients with optic neuropathy may show spontaneous 
improvement. In one analysis of 32 untreated eyes, 19% had final 
visual acuity ranging from counting fingers to no light 
perception.  
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LABORATORY EVALUATION 
1. TSH (Thyroid Stimulating Hormone) 
a. The most useful and most sensitive initial thyroid function test 
especially for screening outpatients. Sub – clinical disease is 
detected earlier with serum thyroid stimulating hormone than 
with conventional hormone studies. In addition thyroid 
stimulating hormone levels are not affected by alteration in 
thyroid – binding proteins. 
It is useful in following patients receiving thyroid hormone therapy. 
i.   Sub clinical hypothyroidism - elevated 
ii.  Hyperthyroidism -  suppressed 
iii. Euthyroid ophthalmopathy - decreased level in the presence 
of  normal levels of T3 and T4 
 - The Immune radio 
immunoassay method can 
measure very low levels of 
serum thyroid stimulating 
hormone and hence a very 
sensitive test. 
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b. Elevated basal thyroid stimulating hormone levels with 
successive response to thyroid releasing hormone indicates 
primary hypothyroidism. 
o Absence of thyroid stimulating hormone response to 
thyroid releasing hormone with low T3, T4 and thyroid 
stimulating hormone – pituitary deficiency. 
o Partial or normal response of thyroid stimulating hormone 
to thyroid releasing hormone secretion. 
2. Serum T3 and T4 levels 
 Total serum T3 and T4 levels and the Thyroid Hormone – Binding Ratio 
(THBR), which is measured as T3 resin uptake. This T3 resin uptake test helps 
indirectly measure serum free T4. Both hormones exist in free and bound 
forms. The amount of free hormone is influenced by changes in serum protein 
binding. Serum free T4 is estimated by multiplying the total serum T4 by the 
thyroid hormone binding ratio. The total T4, thyroid hormone binding ratio and 
free T4 values may be altered with primary thyroid disease and with changes in 
serum thyroid – binding proteins. In hyperthyroidism – all are increased. The 
rise in T3 is proportionately more than T4. In hypothyroidism serum levels of T4 
are low and serum T3 is variable. Free T4 is more reliable, as it avoids the 
interfering effects of varying thyroxine binding globulin levels. Free hormone 
levels are more sensitive as they are not vulnerable to levels of thyroxine 
binding globulin. 
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3. Thyroid Antibody Tests 
 Thyroid stimulating Antibody (TSAb) test is available only in research 
laboratories and is important for  
a. Establishing immunological aetiology 
b. Normal value on follow up ascertains a state of complete 
remission. 
c. Diagnosis of Grave’s disease and euthyroid Grave’s 
ophthalmology. 
¾ If there is significant thyroid stimulating antibody titre, 
only reversible measure for control of hyperthyroid state 
should be employed. Antimicrosomal antibodies are 
present in patients with Hashimoto’s disease and to a 
lesser extent in patients with Grave’s disease. Hence 
indicated in possible  
i. Sub-clinical hypothroidism 
ii. Hashimoto’s disease suspects where the thyroid 
stimulating hormone level and anti-microsomal 
antibody levels are elevated. 
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RADIO IODINE UPTAKE SCAN 
131I uptake – measured after 2 hours and after 24 hours. The beta rays 
emitted along with few gamma rays is measured by a Geiger Muller counter. 
Increased uptake occurs in hyperthyroidism. If associated with T3 suppression, 
will determine whether the gland is autonomous or not. No more use 
nowadays. 
For Hyperthyroidism  
1. Free hormone and thyroid stimulating hormone levels in blood. 
2. Thyroid Stimulating Antibody (TSAb) for immunologic basis for 
Grave’s disease. 
3. Assessment of end organ involvement. 
4. Nuclear scanning. 
Measurement of basal thyroid stimulating hormone level by 
radioimmunoassay method provides the most reliable first line test. T3 and T4  
levels are raised; the rise in T3 is proportionately more than in T4. Sometimes, 
only T3 may be raised while T4 is in normal range (T3 thyrotoxicosis). Free 
hormone levels are more sensitive as they are not vulnerable to levels of 
thyroxine binding globulin. Thyroid stimulating hormone is absent or hardly 
detectable in patients with thyrotoxicosis. 
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For Hypothyroidism 
The diagnosis of hypothyroidism can be confirmed by: 
1. Level of thyroid hormone in circulation. 
2. Value of thyroid stimulating hormone and its response to thyroid 
releasing hormone.  
3. Indirect tests like serum enzymes (creatine phosphokinase, lactate 
dehydrogenase) and electrocardiogram. 
4. Thyroid antibody tests. 
5. Others like basal metabolic rate, serum Cholesterol, protein 
bound Iodine, radioactive Iodine 131 uptake tests are not of much 
use in the presence of the more useful tests listed above. 
Thyroid stimulating hormone is the most sensitive test for detection or 
confirmation of sub clinical or overt hypothyroidism. 
Normal Serum Values 
Serum T3   (0.8 to 2.0 ng/ml) 
Serum T4   (4 to 12 µg/dl) 
Serum TSH  (0.5 to 4.5 µIU/ml) 
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IMAGING IN THYROID RELATED ORBITOPATHY 
1. Ultrasonography in Thyroid Related Orbitopathy 
The Ultra-sonography can demonstrate subtle changes occurring in extra 
ocular muscle and orbital fat. These changes are reflected in an irregular 
posterior outline of the retro-bulbar fat pattern, quantifiable enlargement of the 
extra ocular muscles and accentuation of the orbital walls. The enlarged 
muscles show intra muscular echoes due to separation of the muscle bundles. 
Optic neuropathy may be associated with expansion and reduplication of the 
distal portion of the nerve sheath due to expansion of the sub-arachnoids space. 
A scan demonstrates high acoustic reflectively in the muscle bellies due to 
separation of the muscle fibres. 
2. Computed Tomography in Thyroid Related Orbitopathy 
About 90% of patients with thyroid orbitopathy will have bilateral 
computed tomography abnormalities, even if the clinical involvement is 
unilateral. Relatively symmetrical computed tomography findings are seen in 
60% to 70% of patients and any of the extra ocular muscles can be involved. 
Inferior rectus > Medical rectus > Superior rectus > lateral rectus. 
This parallels clinical oculomotor manifestations. 
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Typically the muscle enlargement involves the muscle belly from the 
annulus to the origin of the tendon, and so occurs primarily behind the posterior 
margin of the globe. There are low densities seen within the muscle bellies. 
These areas represent lymphorrhages (focal accumulation of lymphocytes or 
mucopolysaccharide deposition. With long standing disease, larger low-density 
areas may appear in the muscle, probably representing fatty replacement. 
Apical crowding and reduced space around the posterior portion of the 
optic nerve with sharp angulation of the posterior belly of the muscle indicates 
optic neuropathy. 
Coca-cola sign i.e. medial bowing of the medial orbital wall with 
reduction in size of the adjacent ethmoid sinuses. Forward displacement of the 
globe and slight engorgement of the lacrimal gland. Tenting of the posterior 
globe may be due to traction on the globe. 
3. MRI – Non Ionising radiation 
Delineation of compressive optic neuropathy is easier with MRI than 
CT. 
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MANAGEMENT 
Management should consist of a co-ordinated multi-disciplinary, 
medico-surgical approach, based on clinical patho-physiologic inference, 
staging of the disease and knowledge of its effects on the orbital and ocular 
structures. Broadly speaking, management is directed towards abatement or the 
control of inflammation, prevention of ocular and psycho visual damage, 
redressing ocular motor abnormalities, and improving cosmetic disfigurement. 
Managing Graves’ Orbitopathy 
Unless there is an immediate threat to vision, surgical treatment should 
be postponed until the active phase of the disease subsides so as to avoid 
surgical over correction. Sight threatening corneal exposure or optic 
neuropathy may require immediate surgical intervention regardless of the state 
of the disease. 
Treatment of Hyper Thyroidism 
Anti-thyroid drugs – The first-line treatment for hyperthyroidism is 
with Thioimidazole. These reduce systemic symptoms but their benefit with 
regard to Grave’s orbitopathy is questionable. 
Oral Radioactive Iodine Therapy – Many patients become 
hypothyroid within several years after this treatment and require thyroid 
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hormone replacement. Increased incidence of ocular symptoms after 
radioactive iodine therapy has been reported after (131I) (Iodine 131) thus either 
subsequent development or exacerbation of Grave’s ophthalmopathy. 
Surgical Thyroidectomy – It is reserved for patients whose disease 
cannot be controlled with medical treatment or for those who will not tolerate 
or accept radioablation. Some studies show that Thyroidectomy stabilized or 
improved signs of endocrine ophthalmopathy. Subtotal thyroidectomy also 
showed significant improvement in proptosis and in muscle diameter in 
contrast to those treated with radioiodine. 
Medical Management of Orbitopathy 
Steroid Treatment 
These agents probably serve in multiple capacities by suppressing 
immune function and decreasing inflammation, but though the beneficial 
effects are clear the exact mechanism is far from clear. 
Indications: 
a. For any patient with evidence of optic neuropathy, in addition he 
may require radiation or orbital decompression. 
b. For patients with acute orbital inflammation a course of systemic 
steroids will decrease chemosis, injection and proptosis within 
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days. However, some patients require long-term steroid use to 
prevent exacerbation of symptoms. 60 to 100 mg of prednisone 
per day for several days, followed by a slow taper by 5 to 10 mg 
over the subsequent weeks. 
Two – thirds of patients will respond to the above regimen regardless of 
their age, gender or severity of the eye disease. However, chronic, stable 
Graves’ orbitopathy does not respond to steroids or radiation. It is advisable to 
limit the use of steroids to a few months duration, to prevent the numerous side 
effects associated with long-term steroid use. Supplementation with immune 
suppressive therapy or radiotherapy should be considered in the event of 
extended treatment being required. 
Immunosuppressive Therapy – Immunosuppressive agents like 
cyclosporine, cyclophosphamide, methotrexate and azathioprine are reserved 
for rare patients who fail or cannot undergo standard treatment with steroids, 
radiation or surgery. Due to the toxicity associated with this type of immuno 
suppressive therapy the use of these medications has largely reduced. 
Orbital Irradiation – Steroids and local orbital irradiation have similar 
effects or Grave’s orbitopathy and it is unusual for radiation to succeed if 
steroids have not. Radiation typically has no effect on chronic stable Grave’s 
orbitopathy. Dose – 2000 cGy total dose in small fractions, over a period of 2 
weeks to minimize the undesirable side effects. 
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Surgical Management – Multiple surgical procedures involving the 
orbit, muscles and eye lids are often required to correct the functional 
consequences of Grave’s ophthalmopathy. An optimal result is likely if the 
disease has been quiescent for at least  6 months.  
Sequence of surgery – orbital decompression, prior to strabismus 
surgery and finally eyelid surgery. 
Surgeries are mainly to decrease the Exophthalmous or to decrease the 
starring look due to lid retraction. There are newer modalities for treating lid 
retraction like ‘Z’ Myotomy which gives a good cosmetic result especially in 
female patients.  
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AIM OF THE STUDY 
To study in detail about various presentations of thyroid Related 
orbitopathy with special reference to lid retraction and its management  
(Z - MYOTOMY)  
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MATERIALS AND METHODS 
Thyroid orbitopathy was diagnosed in 30 patients who attended 
Regional Institute of Ophthalomology and Government Ophthalmic Hospital 
between May 2004 and August 2005 and they were subjected for detailed 
study. 
Inclusion Criteria 
1. Patients with proptosis of thyroid origin 
2. Patients with lid retraction. 
Exclusion Criteria 
1. Patients with multiple endocrine abnormalities were not included 
in the study. 
2. Patients with proptosis due to cystic lesions were not included. 
3. Patients with suspicious  malignant thyroid disease were not 
included. 
4. Bilateral proptosis due to any other cause. 
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Patients Evaluation 
All patients who were included in the study were worked up in the 
following manner 
1. Detailed History with reference to the  
¾ duration of illness  
¾ onset 
¾ Rate of progression of proptosis 
¾ presence of progressive lid refraction 
¾ prior medical treatement or surgical treatment 
¾ any other associated symptoms. 
2. Complete ocular examination  
¾ Visual acuity by Snellen’s chart 
¾ Examination of orbit and eyelids. 
¾ Examination of eye for IOP with Schiotz tonometry,  
¾ Special emphasis on Hertels exophthalmometer.  
¾ Hess screen 
¾ Extra Ocular Movements 
¾ Colour vision. 
¾ Field of vision. 
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3. Thyroid status evaluation which included 
¾ Thyroid function tests from endocrinology Department 
¾ Radiological investigations like X-ray orbit and CT scan 
¾ USG neck for thyroid mass 
¾ ‘B’ scan for EOM enlargement / to ruled out optic nerve 
compression. 
¾ Radio iodine uptake study using I 131 (or) Tc 99m Pertechnetate 
¾ FNAC / Biopsy of the thyroid gland. 
One or more thyroid evaluation tests were done as per the individual 
case assessment. Results of thyroid function tests were obtained from Govt. 
General Hospital Endocrinology Department. 
Patients were also referred to other departments like ENT, 
OBS/GYNAEC, MEDICAL / SURGICAL OP and ENDOCRINOLOGY to get 
expert opinion regarding diagnosis and management whenever indicated. 
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ANALYSIS AND DISCUSSIONS 
Total numbers of 30 cases reported to our hospital with thyroid eye 
disease were studied. Their clinical profiles were analysed for the following 
parameters. 
a. Age Incidence 
Range No. of Cases Percentage 
16 – 20 yrs 2 6.6% 
21 – 30 yrs 9 30% 
31 – 40 yrs 14 46.6% 
41 – 50 yrs 3 10% 
51 – 60 yrs 2 6.6% 
  
Age incidence varies from 16 – 60 years with highest no. of cases falling 
between 31 – 40 yrs. (J10)   
b. Sex Incidence of Thyroid Orbitopathy. 
Sex Number of cases Percentage 
M 9 30% 
F 21 70% 
 
In our study, a female preponderance ( 70%) was seen as expected in 
any thyroid problem. (11). 
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c. Laterality of Proptosis 
Bilateral 14 63.6% 
Unilateral 8 36.3% 
 
Bilaterality was reported in more than 50% of cases with proptosis 
confirming to the norms of thyroid eye disease. 
d. Direction of Proptosis 
Type Number of Cases Percentage 
Axial 21 70% 
Eccentric 1 3.3% 
No proptosis 8 26.66% 
 
In our study axial displacement of the Globe was more common (70%) (J5) 
e. Complaints 
Complaints No. of cases 
Protrusion 18 
Watering 15 
Retrobulbar Discomfort 15 
 
 Majority of patients complained of watering and RB discomfort (J5)  in 
addition to proptosis.  
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f. Toxic Symtoms 
Symptoms No. of patients 
Weight loss 12 
Tremor 11 
Sweating 8 
Tachycardia 6 
 
The symptoms of thyrotoxicosis were elicited from patients and many of 
them had one or more major toxic symptoms. 
g. Lid Signs 
Though lid signs in thyroid are many and varied, the most important and 
frequently appearing lid signs in the order of frequency of occurrence are 
enumerated here. 
Lid signs 
No. of cases with 
Bilateral presentation 
Cases with 
unilateral 
presentation 
Dalrymple   sign 10 9 
Vongrafe’s   sign 12 6 
Kochers   sign 8 8 
Stellwag   sign 6 6 
Rosenbach   sign 2 2 
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LID SIGNS 
 
     Von Graefe Sign    Griffith Sign 
 
 
 
 
 
          Kocher Sign          Dalrymple Sign  
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h. Visual Acuity 
Vision RE LE 
6/6 – 6/18 26 26 
6/18 – 6/60 2 1 
Less than 6/60 2 3 
 
In our study, thyroid disease did not cause any visual disability and no 
case of compressive optic neuropathy was detected. 
No abnormality was noted in tonometry, pupillary reaction, 
ophthalmoscopy, field charting and colour vision. 
i. Exophthalmometry 
Proptosis Grade Numerical Value No. of eyes Percentage 
Normal <20 18 30% 
Mild 21 – 23 34 56.66% 
Moderate 24 – 27 8 13.33% 
Severe >27   
 
Majority of patients were found to have mild proptosis (56.66%) 
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HERTEL'S EXOPHTHALMOMETRY 
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j. Nature of Thyroid swelling  
Nature of 
Thyroid swelling 
No. of patients Percentage 
Diffuse 18 60% 
Nodular 6 20% 
Multi-nodular 4 13.33% 
No swelling 2 6.6% 
 
In my study, associated thyroid swelling was present in almost all cases 
the details of which and given in the tabular column above. 
k. Thyroid function Tests. 
 T3 T4 TSH %  
Increased 22 22 6 73.33% Hyperthyroid
Decreased 6 6 22 20% Hypothyroid 
(N) Euthyroid 2 2 2 6.6% Euthyroid 
 
In my study hyperthyroid state was strongly associated with thyroid 
orbitopathy as shown above; this correlated with the (J2, J8) 
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NATURE OF THYROID SWELLING 
MULTINODULAR 
 
 
 
 
 
 
 
 
 
 
NO SWELLING 
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 l. Radio Iodine Uptake Scan 
No. of cases Alpha Beta Gamma 
9 7 2 ----- 
 
Thyroid uptake scan showed 
1. Hot nodules   --   (α)in  7 cases  
2. Warm nodules   --  (β) in 2 cases 
3. Cold nodules  --   (γ) Nil 
Which indicates hyperthyroidism is most commonly associated with 
thyroid orbitopathy. 
m. USG orbit – ‘B’ Scan 
No. of cases Muscle Thickening 
No Muscle 
Thickening 
30 12 18 
% 40% 60% 
 
B Scan showed thickening of muscle bellies in 40 % cases.(7) 
n. CT Scan – orbit 
No. of cases EOM Enlargement Normal Study 
11 10 1 
 
CT scan is the study of choice in thyroid Related orbitopathy (J1) but 
only 11 of my patients could afford CT scan. 
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o. Fine Needle Aspiration Cytology of Thyroid Gland 
FNAC was done for 3 patients 
Features suggestive of  Hyperthyroidism 2 
Features suggestive of  Normal Thyroid Gland 1 
 
Out of 3 cases with suspicion of malignancy with TNG, FNAC result 
was negative (FNAC was done by Department of Surgery) at Government 
General Hospital. 
TREATMENT OF THROID 
1. Medical Treatment:  
Antithyroid Drugs Eltroxin 
20 6 
 
2. Radio ablation for 1 patient was given at Nuclear Medicine Department 
Government General Hospital. 
3. 2 patients have undergone thyroidectomy for hyperthyroidism at Govt. 
General hospital few years back. 
Majority of my patients (twenty) were treated with antithyroid drugs and 
six of them were treated with thyroxine. 
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RADIO IODINE UPTAKE 
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'B' SCAN 
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CT SCAN - ORBIT 
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OCULAR TREATMENT 
Lubricating Drops Oral steroids Immunosuppressants 
30 19 1 
 
In my study simple conservative measures like lubricating drops was 
applicable to all my 30 patients (J5).  All my male patients were advised to stop 
smoking as it is known to aggravate the condition (J9). 
19 patients were treated with oral prednisolone and they showed good 
response with decreased (or) static exophthalmous11. 
Immunosuppressants are reserved for those not responding to steroids 
because of its toxicity11 (J2).  
In my study it was started for a single patient but unfortunately the 
patient was lost for follow up.  
As it was reported literature (J7) patients not responding to steroids show 
poor response to radiotherapy. It was not tried for steroid, unresponsive 
patients. 
Orbital decompression is indicated for compressive optic neuropathy 
and for disfiguring exophthalmos11 (J2) in thyroid related orbitopathy which 
was not noted in any of our cases. 
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SURGERY 
Cosmetic Eyelid Surgery 
- ‘Z’ MYOTOMY in  5 patients 
In our special clinic patients, especially young females complained of 
cosmetic problems due to lid retraction and they did not have visual 
impairment. These patients were selected for ‘Z’ myotomy after their thyroid 
disease has been non-progressive for atleast 6 months. 
After the satisfaction of selection criteria, 5 of my patients underwent ‘z’ 
myotomy for lid retraction with excellent results. 
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SCHEMATIC ILLUSTRATION OF 'Z' MYOTOMY 
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Z-MYOTOMY 
Incision         Hooking the Levator 
 
 
 
 
      Dissecting, Levator aponeurosis       Levator cut in Z configuration 
 
 
 
 
Post op - On the table    Post-op  
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SUMMARY 
 Thirty cases of TRO who attended our special clinic were subjected for 
detailed study. 
 The age group ranged from 16-60 yrs, more than 50% falling between 
30-50 yrs. 
 As expected in any thyroid disease, females are more affected i.e., 70% 
 63.6% showed bilateral involvement with 70% of them having axial 
proptosis. 
 Symptoms of thyrotoxicosis were present in almost all cases. 
 Bilateral lid retraction associated with even minimal proptosis is the 
most frequently occurring problem, for which patient needed a good 
cosmetic relief 
 In my study no abnormality was noted because of  Thryoid Related 
Orbitopathy in Visual Acuity, Tonometry, Pupillary reaction, 
Ophthalmoscopy, Fields, Colour Vision and Ocular Movements. 
 More than 55% of pt. had only mild proptosis and 93% of TRO had 
associated thyroid swelling also. 
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 In doing Thyroid Function Test, 73% showed hyperthyroid, 20% 
hypothyroid 7% showed Euthyroid states.  Radio active iodine uptake 
done in 9 pts, 7 of them showing hot nodules, 2 of them warm nodules. 
No patient had cold nodules. 
 USG {B Scan} was done as a screening procedure in all cases of TRO 
Of these 83% showed Extra OcularMuscle enlargement in CT scan too. 
 Regarding the treatement 20 patients were put on antithyroid drugs 
while 6 on thyroxine and 2 patients under went thyroidectomy. 
 Regarding surgical modalties, most of them wanted good cosmesis and 
relief from starring look due to lid retraction associated with 
exophthalmous.  
 Surgical procedure of marginal Z myotomy was carried out in 5 patients 
who had stable TRO and thyroid status and all of them showed great 
improvement, after surgery cosmetically. However, longtime followup 
is awaited in these patients. 
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CONCLUSION 
 Most of the patients who come for ophthalmic department with TRO are 
females belonging to 30 – 50 yrs of age. 
 Surprisingly they do not have visual problems (nor) show signs of optic 
nerve compression. 
 Though many of them had toxic thyroid symptoms and swelling, even 
enlargement of EOM on USG, ‘B’ scan orbit and CT scan the proptosis 
was mostly minimal. 
 Many of them were on medical Treatement associated with proptosis for 
thyroid and required systemic steroids for arresting progression of 
ophthalmic disease. 
 The most important reason for consulting ophthalmologists is to get a 
good cosmetic appearance since many of these patients have marked lid 
retraction, with even minimal proptosis, cause an ugly starring look 
either unilaterally or bilaterally. 
 Simple procedure of marginal ‘z’ myotomy gives good acceptable 
cosmetic results in these patients and this procedure can be done easily 
by all ophthalmologists and there is no requirement for special 
instruments and sutures.  However, long term effect and results of this 
procedure are to be evaluated. 
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Part - III 
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PROFORMA 
STUDY OF THYROID RELATED ORBITOPATHY 
 
Name :   Age & Sex :     Date   : 
 
Address :   Height & Weight   IP/OP : 
 
Occupation    Unit      
 
COMPLAINTS AND DURATION  
 a. Protrusion of eyeball 
 b. Watering  
 c. Sandy sensation/Retro bulbar discomfort. 
 
H/O PRESENT ILLNESS 
 Protrusion of Eyeball / Onset 
  Sudden/Gradual and Progressive / Intermittant 
 Defective Vision 
  Diplopia / Colour vision / field of vision 
 Periocular Pain  
  Stationary / Progressive / Intermittent 
 Toxic symptoms : 
Weight Loss/Tachycardia/Tremor/Sweating/Changes in the nail, 
skin, and hair, 
H/O Heat Intolerance/Cold Intolerance : Tuberculosis/Diabetes Mellitus / 
Hypertension 
 
PAST HISTORY 
 Thyroid Dysfunction / Malignancy / Trauma / Sinus. 
 81
PERSONAL HISTORY : 
MENSTRUAL HISTORY : 
FAMILY HISTORY : 
PHOTOGRAPH : 
COMPARISON  
LOCAL EXAMINATION : 
LIDS  HI H 
Dalrymple Sign (Lid Retrction)    
Von Graefe sign (Upperlid-lag on downgaze)   
Kocher sign (Starring and frightened appearance)   
Stellwag sign (Infrequent blinking)   
Rosenbach sign (Tremor of the closed lid)   
Grove sign (Upper lid resistance to downward 
traction) 
  
Griffith sign (Lower-lid lags behind the globe on 
upward gaze) 
  
Means sign (Globe lags behind upper lid on upgaze)   
Jellinek sign (Increased pigmentation of the lidskin)   
Gifford sign (Prevent eversion of upper lid)   
Enroth sign (Fullness of the eyelids)   
Mobius sign (Weakness of Convergence)   
 
CONJUNCTIVA : 
 Chemosis / Hyperaemia / superior limbic Keratoconjunctivitis 
CORNEA : 
 Exposure Keratitis / Ulcer / Keratoconjunctivitis Sicca 
PUPIL : 
 Restricted / Diplopia 
DISTANT VISION RF LE 
Without Glass   
With Glass   
   
NEAR VISION RE LE 
Without Glass    
With Glass    
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COLOUR VISION : 
 Normal / Impairment  
FIELD OF VISION : 
 Central scotoma / Paracentral scotoma / combined 
FUNDUS : 
 Normal / Vascular Congestion / Swelling / Atrophy of the optic nerve / 
INTRAOCULAR PRESSURE : 
 Primary position / Differential gaze 
SLIT LAMP EXAMINATION : 
 Presence of tortuous vessels / Hypertrophy Lateral rectus / Superior 
limbic Kcratoconjunctivitis 
 
EXAMINATION OF ORBIT RE LE 
Proptosis-Axial / Eccentric 
With Bruit 
Without Bruit  
  
Valsalva 
Compressibility / Retropulsion 
  
Transillumination 
Orbital Mass 
Tenderness 
Swelling  
  
 
EXOPHTHALMOMETRY : 
BASAL :    1 Visit  II Visit   III Visit  
 
FORCED DUCTION TEST : 
 
DIPLOPIA AMOUNT : ASSESMENT  
 Hess Screen 
EXAMINTION OF THE THYROID GLAND 
 Thyroid swelling : diffuse / Nodular / Multinodular 
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GENERAL EXAMINATION : 
 Pulse rate / Rhythm / Volume / Sleeping pulserate / Temperature / BP 
SKIN, HAIR AND NAIL CHANGES, PRETIBIAL MYXOEDEMA  
INTERDISCIPLINARY CONSULTATIONS  
ENDOCRINOLOGY   OB/GYN  OTHERS 
MEDICAL / SURGICAL   ENT 
 
INVESTIGATION : 
 Blood :   Urine : Albumin  Sugar 
 
 Thyroid Function Test 
 Serum 
  T3  
  T4 
TSH   
 
ULTRASONOGRAM : 
 Enlargement EOM / RB Fat volume / Optic Nerve 
CT SCAN : 
 Enlargement of Extraocular muscles / Optic Nerve Compression 
MRI : 
FNAC / BIOPSY : 
FINAL DIAGNOSIS 
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TREATMENT : 
PREVIOUS : 
 Anti-thyroid drugs – Propyl-thiouracil and β-blockers/eltroxin 
Radioactive iodine therapy – Corticosteroids / Cytotoxic agents / 
Injection botulinum toxin / Surgery. 
 
PRESENT : 
 Topical therapy – Lubricant Drops  
Systemic therapy – Corticosteroids / Cytotoxic agents /  
Anti-thyroid drugs Radiotherapy  
 
SURGICAL THERAPY RE LE 
Lateral tarsorrhaphy / Z. Myotomy   
Recession of Levator and Muller’s Muscle Surgery   
Blepharoplasty   
Orbital Decompression   
One wall / Two wall / Three wall & Four Wall   
 
FOLLOW-UP ADVICE : 
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INDEX TO THE MASTER CHART 
 
1. Serial number 
2. Name 
3. Age 
4. Sex 
5. Weight 
6. Complaints & Duration 
a. Protrusion of eyeball 
b. Watering of eye 
c. Sandy sensation / Retrobulbar discomfort 
7. Protrusion of Eyeball 
S. Sudden 
G. Gradual 
P. Progressive 
I. Intermitent 
8. Toxic Symptoms 
*      Weight Loss 
O     Tachycardia 
T Tremor 
 Sweating 
  Changes in nail / skin / hair 
9. Lid Signs 
1. Dalrymple sign 
2. Von Graefe sign 
3. Kocher sign 
4. Stellwag sign 
5. Rosenbach sign 
6. Grove sign 
7. Griffith sign 
8. Means sign 
9. Jellineck sign 
10. Gilford sign 
11. Enroth sign 
12. Mobius sign 
10. Fundus 
N. Normal 
P. Papilloedema 
11. IOP 
12. SLE – Slit Lamp Examination 
i. Presence of tortuous vessels 
j. Hypertrophy of lateral rectus 
k. Superior limbic keratoconjuntivitis 
13. Visual Activity 
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14. Orbital Proptosis 
A. Axial 
E. Eccentric 
15. Exophthalmometry 
16. Thyroid Examination 
D. Diffuse 
N. Nodular 
MN. Multi nodular 
17. Thyroid Function Test 
L  Decreased 
K  Increased 
- Normal 
 
18. Thyroid Uptake Scan 
α  Hot Nodule 
β  Warm nodule 
γ  Cold nodule 
19. USG orbit 
MT. Muscle thickening 
20. CT Scan 
EOM – Extra ocular muscle enlargement 
21. FNAC Thyroid 
HT. Hyper thyroid picture 
NT. Normal Thyroid picture 
22. Past Treatment 
AT. Antithyroid 
S. Surgery 
R. Radioactive iodine 
23. Present Treatment 
LD. Lubricating Drops 
OS. Oral Steroids 
OR. Orbital Irradiation 
I. Immunosuppression 
     24.Surgical Treatment Eyelid / Orbit 
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MASTER CHART 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
                RE LE   RE LE   RE LE RE LE RE LE   T3 T4 TSH               
1 Dowlath 37 F 60 a c G - 1,2 - N 17.3 17.3 - 6/9 6/9 A A 21 22 D K K L β MT EOM - AT LD/OS  
2 Shankar 27 M 56 a b G - 1,2,3,6 3 N 14.6 14.6 I 6/6 6/6 A A 21 22 D K K L α MT EOM - AT LD/RT  
3 Malar 35 F 40 a c P * o T  1,2 - N 17.3 14.6 - 6/6 6/6 A A 21 23 N K K L α N - - AT LD/OS Z Myotomy 
4 Pitchaiammal 60 F 48 c G * - T  1,2 - N 10.2 14.3 - 6/24 6/60 A A 21 22 N K K L − N - - AT LD  
5 Lakshmi 42 F 47 b - * - T - 2 - N 17.3 17.3 - 6/6 6/6     D K K L − N - - AT LD/OS  
6 Ranjankani 16 F 26 a c P * - -  1,2,3 1,2,3,5,6 N 17.3 17.3 - 6/6 6/6 A A 22 24 MN K K L α MT EOM - AT LD/OS Z Myotomy 
7 Ramasamy 50 M 48 a c G - o T - 1,2 1,2 N 14.6 14.6 - 5/60 5/60 A A 21 22 MN K K L α MT EOM - AT LD/OS  
8 Veeraraghavan 27 M 46 a c G  o T  1,2,3,4,8,9,11 - N 20.1 17.3 - 6/6 6/6 A A 22 21 D K K L − N - - S LD/OS (Ims)  
9 Sumathy 27 F 46 a c P * - - - - 1,2,3 2,3,5,6,7 N 14.6 14.6 - 6/6 6/6 A A 22 20 MN K K L α MT EOM - AT LD/OS  
10 Suresh 22 M 50 a c G * - - - - 2,4 2 N 17.3 17.3 - 6/6 6/6 A A 22 24 N L L K − N - - AT LD/OS  
11 Shanthy 32 F 82 b G - 1 1 N 17.3 17.3 - 6/6 6/6 A A 21 22 D L L K − N - - Eltroxin LD  
12 Jhansi Rani 28 F 58 b c - - - - N 17.3 17.3 - 6/6 6/6      K K L − N - - Eltroxin LD  
13 Murugan 45 M 65 a b G - 1,3,7,8,10,12 1,2,3 N 17.3 17.3 - 6/6 6/6 A A 22 24 D K K L − MT EOM HT AT LD/OS 
Orbital 
Decompression
14 Perumal 39 M 55 a c P * - - - - 1,3 1,3 N 17.3 17.3 - 6/6 6/6 A A 24 22 N K K L − MT EOM - AT LD/OS  
15 Sharmila 22 F 36 a P * o T  1,5 1,5 N 17.3 17.3 - 6/6 6/6 A A 22 21 MN L L K − N - - Eltroxin LD  
16 Dayamani 35 F 48 b - - - - N 14.6 14.6 - 6/6 6/18     N K K L − N - - S/AT LD/OS  
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17 lakshmi 31 F 60 b - - - - N 14.6 14.6 - 6/6 6/6      L L K − N - NT Eltroxin LS  
18 Shalma 38 F 56 b P - - T - 4 1,2,3 N 17.3 17.3 - 6/6 6/6 A A 24 21 D L L K − MT - - Eltroxin LS Z Myotomy 
19 Rajeswari 37 F 60 b G - - T - 2,9 2,3,5,9 N 17.3 17.3 - 6/12 6/6 A A 24 21 D K K L − N - - AT LD/OS  
20 Vijayalakshmi 25 F 45 b - - 2,3 2,3 N 17.3 17.3 - 6/6 6/6     D K K L − N - - AT LD/OS  
21 Vasuki 35 F 60 b - - 1 1,2 N 17.3 17.3 - 6/6 6/6 A E 21 22 D N N L − N - -  LS  
22 Vijaya 35 F 60 a b G * o T  1,3,4 1,3,4,8 N 17.3 17.3 - 6/60 6/60     N N N L − N - -  LS  
23 Zareena 33 F 46 a b c G - - T  1,2,3,4,6 1,2,4,5,6 N 14.6 14.6 - 6/6 6/6 A A 24 22 D K K L − N - HT AT LD/OS  
24 Fathima 17 F 35 a G * - -  5 1,5 N 17.3 12.2 - 6/9 6/9 A A 21 23 D K K L β MT EOM - AT LD/OS  
25 Nirmala 35 F 60 a c P - - - -  - 1 N 14.6 14.6 - 6/6 6/6 A A 21 23 D K K L − N - - AT LD/OS  
26 Dhanalakshmi 38 F 55 c G - 1,2,3,4,6 1,5 N 17.3 17.3 - 6/6 6/6     D K K L − MT Absent - AT LD/OS Z Myotomy 
27 Mohanavel 39 M 58 a c G * - T - 1 1 N 14.6 14.6 - 6/6 6/6 A A 21 21 D K K L α N - - AT LD/OS Z Myotomy 
28 Justin Paul 30 M 62 a b G - 2 2 N 17.3 17.3 - 6/6 6/6 A A 21 22 D K K L − MT EOM -  LD/OS  
29 Abaraj 60 M 60 a c G * - - - - 1,3 1,3 N 14.6 17.3 - 6/24 6/24 A A 21 22 D K K L α N - - AT LD/OS  
30 Subhashini 27 F 50 b - - - - N 17.3 17.3 - 6/9 6/9     D L L K − N - - Eltroxin LS  
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